Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion. The deal announced on Thursday gives ...
Novo has struck a 1.165 billion euro ($1.33 billion) deal to combine Nanexa’s long-acting injectable drug delivery platform with the Big Pharma's obesity and Type 2 diabetes drugs. The agreement gives ...
Novo set out ambitions to launch more than five potential multi-blockbuster drugs by 2030 on Monday, but shares fell 8%. Analysts said the update offered little new to restore confidence after the ...
The key sentence in the company's announcement about its name change is this one: "As part of this, we will embrace the shorthand 'Novo' as our day-to-day name, while Novo Nordisk A/S remains our ...
Novo Nordisk (NVO) is eyeing the hair-loss market as the Ozempic maker looks to diversify as part of its post-Wegovy growth strategy, Bloomberg reported on Tuesday following an interview with its top ...
Novo Nordisk A/S is eyeing the hair-loss market as the maker of Ozempic seeks to expand its direct-to-consumer pharmaceuticals business. The condition is part of a list of areas, including addiction ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Novo Nordisk on Monday ...
Novo Nordisk NOVO.B2.14%increase; up pointing triangle Chief Executive Mike Doustdar, who took over in 2025 promising to find a sustainable growth path, said the company will launch several new ...
Novo Nordisk’s stock closed lower on Monday as the weight-loss-drug giant failed to reassure investors about its strategy going ahead. At an investor event on Monday, Novo set out its 2030 ambitions, ...
Sept 16 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has partnered with Anthropic to use the AI giant's Claude models to speed up discovery and development of new medicines, the companies said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results